KH-631 is under clinical development by Chengdu Kanghong Pharmaceuticals Group and currently in Phase I for Wet (Neovascular / Exudative) Macular Degeneration. According to GlobalData, Phase I drugs for Wet (Neovascular / Exudative) Macular Degeneration have an 89% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how KH-631’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

KH-631 overview

KH-631 is under development for the treatment of neovascular (wet) age-related macular degeneration (nAMD). It is administered through intraocular and sub-retinal (ophthalmic) route. It cats by targeting vascular endothelial growth factor (VEGF).

Chengdu Kanghong Pharmaceuticals Group overview

Chengdu Kanghong Pharmaceuticals Group (Kanghong Pharmaceuticals) develops, manufactures and markets Chinese medicines, chemical drugs and biological products. It offers products for the treatment of medical conditions related to the central nervous system, ophthalmology, digestive system, gastrointestinal and diabetes among others. Kanghong Pharmaceutical products include Lumitin, Bosiqing, Bolexin, Danshu, Xinluona, Shuganjieyu, Yiqing, Keluoxin, Yitanning and Xuanmaiganju. The company offers its products in the form of dispersible tablets, ophthalmic injections, oral drugs, detoxification drugs and antiviral medicines. Kanghong Pharmaceuticals is headquartered in Chengdu, Sichuan, China.

For a complete picture of KH-631’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.